Diversified Trust Co Has $10.51 Million Stock Holdings in Amgen Inc. (NASDAQ:AMGN)

Diversified Trust Co lessened its position in Amgen Inc. (NASDAQ:AMGN) by 2.0% during the 1st quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 36,949 shares of the medical research company’s stock after selling 746 shares during the period. Diversified Trust Co’s holdings in Amgen were worth $10,505,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds also recently made changes to their positions in the company. BOK Financial Private Wealth Inc. bought a new stake in Amgen during the 4th quarter worth about $29,000. United Community Bank bought a new stake in Amgen during the 4th quarter worth about $29,000. Planned Solutions Inc. acquired a new position in shares of Amgen during the 4th quarter worth about $30,000. Delos Wealth Advisors LLC grew its position in shares of Amgen by 2,500.0% during the 4th quarter. Delos Wealth Advisors LLC now owns 104 shares of the medical research company’s stock worth $30,000 after buying an additional 100 shares during the period. Finally, Hartford Financial Management Inc. grew its position in shares of Amgen by 56.9% during the 4th quarter. Hartford Financial Management Inc. now owns 113 shares of the medical research company’s stock worth $33,000 after buying an additional 41 shares during the period. Institutional investors and hedge funds own 76.50% of the company’s stock.

Insider Buying and Selling at Amgen

In other Amgen news, SVP Nancy A. Grygiel sold 2,117 shares of the stock in a transaction dated Friday, May 3rd. The stock was sold at an average price of $313.09, for a total value of $662,811.53. Following the completion of the transaction, the senior vice president now directly owns 9,883 shares in the company, valued at $3,094,268.47. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Corporate insiders own 0.69% of the company’s stock.

Amgen Price Performance

Shares of AMGN traded down $0.38 during trading hours on Monday, hitting $312.07. 526,338 shares of the company were exchanged, compared to its average volume of 2,772,451. The company has a market cap of $167.40 billion, a price-to-earnings ratio of 44.64, a P/E/G ratio of 2.82 and a beta of 0.58. Amgen Inc. has a fifty-two week low of $218.44 and a fifty-two week high of $329.72. The company has a quick ratio of 0.98, a current ratio of 1.42 and a debt-to-equity ratio of 11.96. The firm’s fifty day moving average is $301.56 and its 200 day moving average is $292.30.

Amgen (NASDAQ:AMGN) last posted its earnings results on Thursday, May 2nd. The medical research company reported $3.96 EPS for the quarter, beating the consensus estimate of $3.76 by $0.20. The firm had revenue of $7.45 billion during the quarter, compared to the consensus estimate of $7.45 billion. Amgen had a return on equity of 156.21% and a net margin of 12.74%. The business’s quarterly revenue was up 22.0% on a year-over-year basis. During the same period last year, the company earned $3.98 earnings per share. On average, equities analysts anticipate that Amgen Inc. will post 19.47 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several equities analysts recently issued reports on AMGN shares. StockNews.com upgraded Amgen from a “hold” rating to a “buy” rating in a research report on Friday, May 3rd. Royal Bank of Canada boosted their price objective on Amgen from $328.00 to $332.00 and gave the company an “outperform” rating in a research report on Friday, June 14th. Raymond James initiated coverage on Amgen in a research report on Thursday, March 28th. They issued a “market perform” rating for the company. UBS Group upped their price target on Amgen from $284.00 to $307.00 and gave the stock a “neutral” rating in a research report on Friday, May 3rd. Finally, Morgan Stanley upped their price target on Amgen from $271.00 to $310.00 and gave the stock an “equal weight” rating in a research report on Friday, May 3rd. Ten investment analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $307.35.

Amgen Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.